STOCK TITAN

ENvue Medical (FEED) insider exits 210,000-share position in open-market sale

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ENvue Medical, Inc. insider Christian Michael Glibert reported an open-market sale of 210,000 shares of Common Stock at an average price of $0.688 per share. The sale was executed in multiple transactions with prices ranging from $0.6756 to $0.722. Following this transaction, the filing shows that Glibert directly holds 0 shares of ENvue Medical common stock.

Positive

  • None.

Negative

  • None.

Insights

Insider fully exits direct ENvue Medical share position.

The filing shows Christian Michael Glibert executed an open-market sale of 210,000 shares of ENvue Medical common stock at an average price of $0.688 per share. Trades occurred across a price range from $0.6756 to $0.722.

After this sale, reported direct ownership falls to 0 shares, indicating a complete exit of his directly held common stock position in this filing. There are no remaining derivative securities reported, so the visible equity exposure associated with this Form 4 consists solely of the disposed shares.

The filing does not reference a Rule 10b5-1 trading plan, so the transactions appear as discretionary open-market activity. Future company filings may provide additional context on broader ownership changes among other insiders or major holders.

Insider Glibert Christian Michael
Role null
Sold 210,000 shs ($144K)
Type Security Shares Price Value
Sale Common Stock 210,000 $0.688 $144K
Holdings After Transaction: Common Stock — 0 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares sold 210,000 shares Open-market sale of common stock
Average sale price $0.688 per share Common Stock transaction
Price range $0.6756–$0.722 per share Footnote: multiple transactions
Shares owned after 0 shares Total direct holdings following transaction
open-market sale financial
"transaction_action: "open-market sale" for the common stock transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"security_title: "Common Stock" in the reported transaction"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Section 16 regulatory
"other: "No longer subject to section 1" indicating Section 16 status"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Glibert Christian Michael

(Last)(First)(Middle)
4001 GREEN HERON SPRING DRIVE

(Street)
CARPINTERIA CALIFORNIA 93013

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ENvue Medical, Inc. [ $FEED ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
Officer (give title below)XOther (specify below)
No longer subject to section 1
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/22/2026S210,000D$0.688(1)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares were sold in multiple transactions ranging from $.6756 to $.722.
/s/ Christian Michael Glibert06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Christian Michael Glibert report in the ENvue Medical (FEED) Form 4?

He reported an open-market sale of 210,000 shares of ENvue Medical common stock. The average sale price was $0.688 per share, and the transactions were executed across a defined intraday price range.

How many ENvue Medical (FEED) shares did the insider sell and at what price?

He sold 210,000 shares of ENvue Medical common stock at an average price of $0.688. According to the footnote, individual trades occurred between $0.6756 and $0.722 per share.

Does the Form 4 show any ENvue Medical (FEED) shares remaining after the sale?

The Form 4 indicates total shares of ENvue Medical common stock directly owned after the transaction are zero. This suggests the reported insider no longer holds a direct common stock position in this filing.

Were the ENvue Medical (FEED) insider sales under a Rule 10b5-1 trading plan?

The filing’s footnote describes sales across a price range but does not reference any Rule 10b5-1 trading plan. The transactions are therefore presented simply as open-market sales in this report.

What type of security did the ENvue Medical (FEED) insider sell?

The insider sold shares of ENvue Medical’s Common Stock. No derivative securities or option exercises are reported in this Form 4, and the derivative section for this filing is empty.